Folate receptor targeted nanoparticles containing niraparib and doxorubicin as a potential candidate for the treatment of high grade serous ovarian cancer

Lucy Lu Wang, James Evans, Lubabah Ahmed, Christine Allen

TL;DR

This paper presents a novel dual-drug nanoparticle designed to deliver a synergistic combination of niraparib (a PARP inhibitor) and doxorubicin to high-grade serous ovarian cancer (HGSOC) cells. By encapsulating these drugs at a specific ratio within folate-targeted liposomes, the researchers aim to improve treatment efficacy and reduce systemic toxicity, addressing a critical unmet need in ovarian cancer therapy.

What Problem Does This Paper Address?

Ovarian cancer, particularly high-grade serous ovarian cancer (HGSOC), remains a leading cause of cancer-related deaths with limited therapeutic advancements in recent years. While combination chemotherapy offers improved efficacy, it often leads to dose-limiting toxicities, primarily hematological. The FDA approval of Vyxeos®, a liposomal formulation delivering a synergistic drug combination, highlights the potential of nanoparticle-based delivery for enhanced outcomes. This study addresses the challenge of effectively delivering synergistic drug combinations, specifically a PARP inhibitor (niraparib) and a chemotherapeutic agent (doxorubicin), to ovarian cancer cells while minimizing off-target toxicities. The researchers aim to overcome the limitations of traditional chemotherapy by developing a targeted nanoparticle that delivers these drugs at a precisely determined synergistic ratio.

Methods

The study employed a multi-faceted approach:

  • In Vitro Synergy Screening: A panel of HGSOC cell lines was used to screen various molar ratios of niraparib (NIRB) and doxorubicin (DOX) to identify synergistic combinations. The Chou-Talalay method, implemented via CompuSyn software, was used to calculate Combination Index (CI) values, with thresholds defined for synergy (CI ≤ 0.9), additivity (0.9 < CI < 1.1), and antagonism (CI ≥ 1.1).
  • Nanoparticle Formulation: A dual-drug loaded liposome was formulated. This involved:
  • Unloaded Liposome Preparation: Using hydrogenated soybean phosphatidylcholine (HSPC), cholesterol, and DSPE-PEG2000.
  • Drug Loading: Active loading of NIRB and DOX into the liposomes using a pH gradient and triethylammonium sucrose octasulfate (TEA SOS) as an entrapment agent. This method was chosen to achieve a controlled, synergistic molar ratio.
  • Folate Targeting: Post-insertion of folate-PEG5k-DSPE to create folate receptor-targeted liposomes (NIRB-DOX-FA).
  • Liposome Characterization:
    • Size and Encapsulation Efficiency: Determined by Dynamic Light Scattering (DLS) and HPLC-UV analysis.
  • Drug to Lipid Ratio: Quantified using HPLC-UV and lipid quantification.
  • In Vitro Drug Release: Assessed under sink conditions in bovine serum albumin (BSA) enriched buffer over five days.
  • Cryo-Transmission Electron Microscopy (Cryo-TEM): Used to visualize the morphology of loaded and unloaded liposomes and assess drug precipitation within the liposomal core.
  • Cellular Uptake Studies: Folate receptor alpha (FRα) expression was evaluated using flow cytometry. Cellular uptake of folate-conjugated versus unconjugated calcein-loaded liposomes was then assessed in FRα-high and FRα-low expressing cell lines.

Datasets

  • Ovarian Cancer Cell Lines: A panel of four HGSOC cell lines (OVCAR8, HEYA8, PEO1, and PEO4) were used for in vitro synergy screening and FRα expression analysis. The MCF7 breast cancer cell line was used as a negative control for FRα expression.
  • No new benchmarks were introduced.

Key Insights and Ideas

  • Synergistic NIRB:DOX Ratio Identified: The study successfully identified a consistent synergistic or additive effect for the combination of niraparib and doxorubicin across multiple ovarian cancer cell lines, particularly at a 10:1 molar ratio (NIRB:DOX). This ratio was found to be crucial for achieving synergistic outcomes.
  • Homologous Recombination Repair (HRR) Dependency: The synergistic effect of the NIRB:DOX combination appears to be dependent on the homologous recombination repair (HRR) status of the cells. The PEO4 cell line, which exhibits HR proficiency (potentially due to BRCA2 mutation reversion), showed antagonistic effects, contrasting with the synergistic/additive effects observed in HR-deficient cell lines like PEO1. This suggests that HR-proficient tumors might be less responsive to this combination.
  • Targeted Delivery Enhances Uptake: Folate targeting significantly improved the cellular uptake of liposomes in FRα-overexpressing OVCAR8 cells, while no such enhancement was observed in FRα-low expressing HEYA8 cells. This validates the strategy of using folate targeting for selective delivery to ovarian cancer cells.
  • Stable, Dual-Drug Encapsulation: The researchers developed a stable liposomal formulation capable of co-encapsulating NIRB and DOX at the desired synergistic ratio. The use of TEA SOS as an entrapment agent facilitated the formation of an electron-dense drug core, contributing to sustained in vitro drug release and improved liposome stability.
  • Potential for Overcoming Resistance: The development of this targeted nanoparticle formulation offers a promising avenue for overcoming drug resistance and improving treatment outcomes in ovarian cancer, particularly by delivering a synergistic drug combination at a controlled ratio.

Key Results

  • Synergistic/Additive Effects: The 10:1 NIRB:DOX molar ratio demonstrated consistent synergistic or additive effects in the majority of tested HGSOC cell lines at both 50% and 75% cell death fractions (Fa=0.5 and Fa=0.75).
  • Antagonism in HR-Proficient Cells: The PEO4 cell line, representing HR-proficient tumors, exhibited a general trend towards antagonism for all tested NIRB:DOX molar ratios.
  • FRα Overexpression: OVCAR8 cells showed significantly higher FRα expression compared to other cell lines and a negative control.
  • Enhanced Cellular Uptake: Folate-conjugated liposomes showed significantly higher uptake in OVCAR8 cells compared to unconjugated liposomes.
  • Liposome Characteristics: The optimized NIRB-DOX-FA liposomes had a size of 124.6 ± 53.9 nm, an encapsulation efficiency of 87.6 ± 19.9% for NIRB and 71.5 ± 17.3% for DOX, and a resultant NIRB:DOX molar ratio of 9.4 ± 0.6:1.
  • Sustained Drug Release: In vitro release studies showed minimal drug release from NIRB-DOX-FA liposomes over a 5-day period, maintaining the encapsulated NIRB:DOX molar ratio.

Limitations and Future Work

  • Limited Cell Line Panel: The authors acknowledge that the study used a small panel of ovarian cancer cell lines. They suggest that screening a larger panel, including additional platinum-resistant cell lines, is crucial to understand the combination's performance across a broader spectrum of disease heterogeneity.
  • HRR Dependency: The observed dependence of synergy on HRR status suggests that patient selection based on BRCA status might be necessary for optimal therapeutic outcomes. Further investigation is needed to confirm this hypothesis.
  • In Vivo Validation: While the in vitro results are promising, in vivo studies are necessary to evaluate the efficacy, pharmacokinetics, biodistribution, and toxicity of the NIRB-DOX-FA nanoparticles in relevant animal models.
  • Mechanistic Understanding: The precise mechanisms underlying the synergistic and antagonistic effects of the NIRB:DOX combination require further elucidation, particularly concerning the interaction with the DNA damage response (DDR) network.
  • Clinical Trial Termination: The authors note the termination of a previous clinical trial combining niraparib and liposomal doxorubicin, suggesting that a better understanding of patient selection criteria (e.g., HR proficiency) and drug combination mechanisms is essential for future clinical translation.

Summary updated

Abstract

Combination chemotherapy is an established approach used to manage toxicities while eliciting an enhanced therapeutic response. Delivery of drug combinations at specific molar ratios has been considered a means to achieve synergistic effects resulting in improvements in efficacy while minimizing dose related adverse drug reactions. The benefits of this approach have been realized with the FDA approval of Vyxeos®, the first liposome formulation to deliver a synergistic drug combination leading to improved overall survival against standard of care. In the current study, we demonstrate the synergistic potential of the PARP inhibitor niraparib and doxorubicin for the treatment of ovarian cancer. Through in vitro screening in a panel of ovarian cancer cell lines, we find that niraparib and doxorubicin demonstrate consistent synergy/additivity at the majority of evaluated molar ratio combinations. Further to these findings, we report formulation of a nanoparticle encapsulating our identified synergistic combination. We describe a rational design process to achieve highly stable liposomes that are targeted with folate to folate-receptor-alpha, which is known to be overexpressed on the surface of ovarian cancer cells. With this approach, we aim to achieve targeted delivery of niraparib and doxorubicin at a pre-determined synergistic molar ratio via increased receptor-mediated endocytosis.
BibTeX
@inproceedings{wang2023folate,
  author = {Lucy Lu Wang and James Evans and Lubabah Ahmed and Christine Allen},
  title = {{Folate receptor targeted nanoparticles containing niraparib and doxorubicin as a potential candidate for the treatment of high grade serous ovarian cancer}},
  booktitle = {Scientific},
  year = {2023},
  doi = {10.1038/s41598-023-28424-3},
}
Figure